The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use

Uemura, Hiroji; DiBonaventura, Marco; Wang, Ed; Ledesma, Dianne Athene; Concialdi, Kristen; Aitoku, Yasuko

doi:10.1080/14737167.2017.1300530

Cited by 9 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies that described the economic burden of AEs in real-world settings have focused on patients with metastatic CRPC or hormone-sensitive (i.e. not castration-resistant) PC 15,16 . No studies have described the real-world burden associated with AEs among nmPC patients using secondary hormonal therapies.…”

mentioning

confidence: 99%

Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy

Shah

Kebede

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

Aims:To describe the incidence and identify prognostic factors of central nervous system (CNS) adverse events (AEs) and any AEs (CNS, skin rash, or fracture) and evaluate the healthcare resource utilization (HCRU), direct medical costs, and therapy discontinuation associated with these AEs among non-metastatic prostate cancer (nmPC) patients who received secondary hormone therapies. Methods and results: nmPC patients who had initiated secondary hormonal therapy with enzalutamide, bicalutamide, or abiraterone 1 year after androgen deprivation therapy (ADT) were identified in the MarketScan database. Survival analyses were used to describe the incidence of CNS or any AEs. Annual HCRU and costs were compared across patient groups (CNS AE vs no CNS AE; any AE vs no AE) using propensity score weighted generalized linear models. Multivariate Cox proportional hazards models were used to identify AE predictors and compare risks of discontinuation. Results: The analysis included 532 patients who initiated secondary hormonal therapies, among whom 201 (38%) and 244 (46%) experienced a CNS AE and any AE, respectively. Median times to CNS AE and any AE from therapy initiation were 17.90 and 11.00 months, respectively. Predictors of any AE were any AE in the baseline period (6 months before starting therapy), Charlson Comorbidity Index (CCI) score (1 vs 0), surgical castration, and older age. Predictors of CNS AEs were CNS AE in the baseline period and CCI score (1 vs 0). CNS and any AEs were associated with significantly higher HCRU. CNS AEs were associated with significantly higher incremental total medical costs ($18,522). CNS AEs and any AEs significantly increased therapy discontinuation risk by 48% and 38%, respectively. Conclusions: AEs increase the economic burden and therapy discontinuation among nmPC patients receiving secondary hormonal therapies subsequent to ADTs. These patients should be carefully evaluated for AEs to reduce therapy discontinuation, HCRU, and direct medical costs. ARTICLE HISTORY

show abstract

mentioning

confidence: 99%

Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy

Shah

Kebede

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…It was observed that the results of the questionnaire were negatively affected by the treatment-related factors, chemotherapy and palliative radiotherapy. Uemura et al Showed that the use of new generation antiandrogens and an symptom control focused active patient follow-up procedures are associated with higher quality of life and lower care burden in bone metastatic prostate cancer patients [20]. Since our study was crossectional, whether the patients had received active chemotherapy in the last 6 months or less (including the time while data was collected) was evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…[27]. In their studies addressing the subject in a similar context, Uemura et al showed that the symptomatic bone event is associated with increased healthcare costs and analgesic use [20]. At this point, the support needs of routine follow-up patients can be measured with systematic measurement methods.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of caregiver burden, and quality of life in metastatic prostate cancer patients and caregivers; Effects of clinical and socioeconomic factors

Yıldırım¹,

Poyraz²,

Erdur³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: To investigate the caregiver burden and quality of life (QoL) of patients with metastatic prostate cancer. The relationship between questionnaire results and medical, socioeconomic, disease and treatment related factors of the patients were evaluated. Methods: One hundred twenty one metastatic prostate cancer patients and caregivers were enrolled in this cross-sectional study. Short Form 36 (SF-36) questionnaires and Zarit caregiver burden interviews (ZCBI) were conducted with patients and their caregivers seperately. Patients’ comorbidities, presence of bone and visceral metastases, bone related events, palliative radiotherapy needs, ECOG scores, being under active chemotherapy, socioeconomic factors such as public transportation need, residential factors and caregiver related factors such as comorbidities and kinships were recorded respectively. Results: Patients’ comorbidities, ECOG score, presence and quantity of bone or visceral metastasis, bone related events, receiving palliative radiotherapy and chemotherapy, using public transportation resulted in lower SF-36 and higher ZCBI results (p < 0.001– p = 0.049). Obligation to live in rented houses were correlated with lower SF-36 physical function results (p = 0.043). Condition of the caregiver being from distant relatives resulted in a lower SF-36 score (p = 0.01 - p= 0.043). Moderate to strong negative correlation was detected between ZCBI and all SF-36 results (p < 0.001, r: -646 to -749). In ZCBI, score over 47 resulted with % 69.57 sensitivity and % 65.52 specificity (AUC = 0.671, p = 0.008). Conclusion: QoL was directly related to caregiver burden. Factors such as patient comorbidities, bone metastasis and related situations, ECOG score, presence of visceral metastasis, actively undergoing chemotherapy, low socioeconomic status and poor family support negatively affect both the quality of life of patients and caregiver burden. If a social assistance system can be implemented in which these factors can be monitored systematically, objective and cost-effective benefits related to the care of these patients and the maintenance of their quality of life can be achieved.

show abstract

“…It was observed that the results of the questionnaire were negatively affected by the treatment-related factors, chemotherapy and palliative radiotherapy. Uemura et al Showed that the use of new generation antiandrogens and an symptom control focused active patient follow-up procedures are associated with higher quality of life and lower care burden in bone metastatic prostate cancer patients 20 . Since our study was cross sectional, whether the patients had received active chemotherapy in the last 6 months or less (including the time while data was collected) was evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…They highlighted the importance of palliative approaches and the rational use of cancer therapies 27 . In their studies addressing the subject in a similar context, Uemura et al showed that the symptomatic bone event is associated with increased healthcare costs and analgesic use 20 . At this point, the support needs of routine follow-up patients can be measured with systematic measurement methods.…”

Section: Agementioning

confidence: 99%

Evaluation of caregiver burden and quality of life in metastatic prostate cancer patients; Effects of clinical and socioeconomic factors

et al. 2021

View full text Add to dashboard Cite

Objective: To investigate the caregiver burden and quality of life (QoL) of patients with metastatic prostate cancer and, to evaluate the relationship between questionnaire results and medical, socioeconomic, disease and treatment related factors of the patients. Methods:One hundred twenty one metastatic prostate cancer patients, and caregivers were enrolled in this cross-sectional study. Patients with metastatic prostate cancer who had at least one bone, lymph node or visceral metastasis who had undergone androgen deprivation or chemotherapy treatments for at least 3 months were included. Short Form 36 (SF-36) questionnaires and Zarit caregiver burden interviews (ZCBI) were conducted with patients and their caregivers seperately. Patients' disease, treatment, socioeconomic and caregiver related factors were recorded respectively.Results: Patients' comorbidities, ECOG score, presence and quantity of bone or visceral metastasis, bone related events, receiving palliative radiotherapy and chemotherapy, using public transportation resulted in lower SF-36 and higher ZCBI results (p<0.001-p=0.049). Obligation to live in rented houses were correlated with lower SF-36 physical function results (p=0.043). Condition of the caregiver being from distant relatives resulted in a lower SF-36 score (p=0.01 -p=0.043). Moderate to strong negative correlation was detected between ZCBI and all SF-36 results (p<0.001, r:-646 to-749). In ZCBI, score over 47 resulted with 69.57% sensitivity and 65.52% specificity (AUC =0.671, p =0.008). Conclusion:QoL was directly related to caregiver burden. Factors such as patient comorbidities, bone metastasis and related situations, ECOG score, presence of visceral metastasis, undergoing chemotherapy, low socioeconomic status negatively affect the quality of life of patients and caregiver burden. If these factors can be monitored, the care and quality of life of these patients can be improved.

show abstract

The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use

Cited by 9 publications

References 16 publications

Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy

Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy

Evaluation of caregiver burden, and quality of life in metastatic prostate cancer patients and caregivers; Effects of clinical and socioeconomic factors

Evaluation of caregiver burden and quality of life in metastatic prostate cancer patients; Effects of clinical and socioeconomic factors

Contact Info

Product

Resources

About